NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$2.1b

Last Updated

2021/05/07 23:51 UTC

Data Sources

Company Financials +

Executive Summary

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Fulgent Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FLGT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: FLGT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-3.1%

FLGT

4.0%

US Healthcare

-0.3%

US Market


1 Year Return

350.2%

FLGT

43.7%

US Healthcare

50.2%

US Market

Return vs Industry: FLGT exceeded the US Healthcare industry which returned 44.2% over the past year.

Return vs Market: FLGT exceeded the US Market which returned 51.8% over the past year.


Shareholder returns

FLGTIndustryMarket
7 Day-3.1%4.0%-0.3%
30 Day-12.8%10.2%2.2%
90 Day-47.3%19.2%3.8%
1 Year350.2%350.2%45.5%43.7%52.7%50.2%
3 Year1,864.2%1,864.2%65.1%58.3%63.4%53.1%
5 Yearn/a112.0%95.8%129.6%104.0%

Long-Term Price Volatility Vs. Market

How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?

4.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: FLGT ($74.64) is trading above our estimate of fair value ($53.04)

Significantly Below Fair Value: FLGT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: FLGT is good value based on its PE Ratio (4.4x) compared to the US Healthcare industry average (23.3x).

PE vs Market: FLGT is good value based on its PE Ratio (4.4x) compared to the US market (20.2x).


Price to Earnings Growth Ratio

PEG Ratio: FLGT's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: FLGT is good value based on its PB Ratio (2.7x) compared to the US Healthcare industry average (3.5x).


Future Growth

How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-63.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLGT's earnings are forecast to decline over the next 3 years (-63.3% per year).

Earnings vs Market: FLGT's earnings are forecast to decline over the next 3 years (-63.3% per year).

High Growth Earnings: FLGT's earnings are forecast to decline over the next 3 years.

Revenue vs Market: FLGT's revenue is expected to decline over the next 3 years (-57.9% per year).

High Growth Revenue: FLGT's revenue is forecast to decline over the next 3 years (-57.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Fulgent Genetics performed over the past 5 years?

97.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLGT has high quality earnings.

Growing Profit Margin: FLGT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 97% per year.

Accelerating Growth: FLGT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: FLGT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (39.8%).


Return on Equity

High ROE: FLGT's Return on Equity (52%) is considered outstanding.


Financial Health

How is Fulgent Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: FLGT's short term assets ($913.9M) exceed its short term liabilities ($197.5M).

Long Term Liabilities: FLGT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FLGT is debt free.

Reducing Debt: FLGT had no debt 5 years ago.

Debt Coverage: FLGT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: FLGT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Fulgent Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Ming Hsieh (64 yo)

5yrs

Tenure

US$248,000

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and serve...


CEO Compensation Analysis

Compensation vs Market: Ming's total compensation ($USD248.00K) is below average for companies of similar size in the US market ($USD3.76M).

Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FLGT's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: FLGT's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FLGT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.


Top Shareholders

Company Information

Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fulgent Genetics, Inc.
  • Ticker: FLGT
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$2.117b
  • Shares outstanding: 28.99m
  • Website: https://www.fulgentgenetics.com

Number of Employees


Location

  • Fulgent Genetics, Inc.
  • 4978 Santa Anita Avenue
  • Temple City
  • California
  • 91780
  • United States

Listings


Biography

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 23:51
End of Day Share Price2021/05/07 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.